Compare · LEXX vs NVO
LEXX vs NVO
Side-by-side comparison of Lexaria Bioscience Corp. (LEXX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEXX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 7857.6x LEXX ($23.4M).
- Over the past year, LEXX is down 25.6% and NVO is down 34.2% - LEXX leads by 8.6 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Lexaria Bioscience Corp.
- Novo Nordisk A/S
- Price
- $0.91-5.96%
- $41.18+6.93%
- Market cap
- $23.4M
- $183.82B
- 1M return
- +13.91%
- +13.32%
- 1Y return
- -25.62%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 5
- Recent ratings
- 0
- 25
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LEXX
- Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
- SEC Form 10-Q filed by Lexaria Bioscience Corp.
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
- Lexaria to Begin New Human Clinical Study in GLP-1
- Lexaria's Robust Patent Portfolio Continues to Grow
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
- SEC Form 4 filed by Bunka Christopher
- Lexaria Announces New R&D Plans for 2026
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S